



Annual Report 2024

**Fondation
Campus
Biotech
Geneva**
+



EXCELLENCE AND
INNOVATION IN
NEUROSCIENCES AND
NEUROTECHNOLOGIES

Foreword

Dear Reader,

The Fondation Campus Biotech Geneva (FCBG) embodies excellence and innovation in the field of neuroscience and neurotechnology. By facilitating collaboration between academic institutions, university hospitals, and industry partners, we have consolidated our position as a world-class research center.

Once again this year, our cutting-edge technology platforms have accelerated innovative projects, demonstrating our commitment to advancing science for the benefit of society.

The FCBG's continuous development is based on a dynamic ecosystem in which each partner plays an essential role. We would like to warmly thank all the researchers, engineers, clinicians, and collaborators who contribute every day to making the Foundation a key player in biomedical research.





The future
looks
bright, with
ambitious
plans to
further
strengthen
the impact
of the
FCBG.


We invite you to discover the highlights of 2024 and share this exciting adventure with us.

Prof. Audrey Leuba, President
Dr. Nicolas Durand, CEO

Table of Contents

6	MISSION & VISION
7	KEY FIGURES
8	THE FCBG ECOSYSTEM
11	GOVERNANCE
12	RETROSPECTIVE
14	MANAGEMENT TEAM
15	ACADEMIC COUNCIL
16	PLATFORM ADVISORY COMMITTEES (PACs)
18	FCBG PARTNERS
20	MAGNETIC RESONANCE IMAGING PLATFORM (MRI)
22	M/EEG & NEUROMODULATION PLATFORM (MEG)
24	PRECLINICAL NEUROSCIENCE PLATFORM (PNP)





26	VIRTUAL REALITY & DIGITAL ENGINEERING PLATFORM (VRD)
28	NEURONA HUMAN CELLULAR NEUROSCIENCE PLATFORM (HCNP)
30	NEURAL MICROSYSTEMS PLATFORM (NMP)
32	CLINICAL & SLEEP RESEARCH PLATFORM (CSR)
34	HEALTH 2030 GENOME CENTER (GC)
36	HUG OUTPATIENT NEUROCLINIC
38	OUR SERVICES
42	RESEARCH & INNOVATION
45	NEURO-CONNECT
46	FINANCIALS
48	VISION



Mission & Vision

The Fondation Campus Biotech Geneva (FCBG)

OUR MISSION


The FCBG's mission is to support and accelerate research and innovation in the field of neuroscience and neurotechnology by providing cutting-edge infrastructure and technology platforms to researchers, clinicians, and entrepreneurs.

Through a collaborative ecosystem, the FCBG catalyzes scientific discoveries to maximize their positive impact on society. By facilitating access to state-of-the-art research equipment and supporting the development of innovative projects, the Foundation plays a key role in promoting translational research and transferring scientific advances to industry.

OUR VISION

Our ambition is to position FCBG as a world-renowned center of excellence and innovation, where the boundaries between scientific and technological disciplines are bridged in order to respond to present-time challenges. We want to create a dynamic, interdisciplinary and inspiring environment that fosters synergy between researchers, engineers, and entrepreneurs in order to accelerate the development of innovative solutions that benefit patients and society.

In a fast evolving world, the FCBG is committed to anticipating scientific and technological trends in the fields of neuroscience and neurotechnology, encouraging interdisciplinarity, and promoting responsible and sustainable research. Through a collaborative approach and proactive governance, we aim to strengthen the impact of our initiatives and make the Foundation a key player in biomedical research and health technologies.



Key figures

10+

platforms
and services

500+

active users on our
platforms

27,600 m²

infrastructure

60+

research groups

15,500 m²

laboratories and
experimental spaces

3

NCCRs actively
supported

1,200

people on site

65

FCBG employees
(30% PhD & 25% MSc)

ANNUAL BUDGET


CHF 29M

The FCBG ecosystem

One of the world's top 10 leading centers for neuroscience and neurotechnology research

The FCBG on the Campus Biotech site


Campus Biotech is leading life science ecosystem in Geneva, promoting interaction and collaboration between academic institutions, healthcare sector, policy makers and companies. Its current site is part of Geneva's industrial heritage, housed in the former red brick buildings of the engineering company Sécheron SA, a flagship of Swiss industry. In 2003, these facilities were acquired by the biotechnology company Serono to establish its global headquarters. Following the acquisition of Serono by Merck KGaA and the company's decision to relocate their operations outside of Switzerland, Campus Biotech was created to reinvest in this space and its infrastructure for enhancing scientific research and development in the Lake Geneva region.



The blue areas indicate FCBG activities, while the green areas correspond to those of other partners present on the Campus Biotech site.

Campus Biotech has established itself as the leading life sciences ecosystem in Geneva, playing a key role in implementing the canton's innovation strategy.

The FCBG hosts leading academic and institutional players, including teams recognized nationally for their expertise in neuroscience and neurotechnology, whose influence extends far beyond Switzerland's borders.



OUR FOUNDING MEMBERS

EPFL

The Ecole Polytechnique Fédérale de Lausanne (EPFL) is one of the top ranking research and education institutions in Europe, renowned for its excellence in science, engineering, and technology. Located on the shores of Lake Geneva, it attracts students, researchers, and entrepreneurs from around the world, fostering ecosystem of basic and applied research, innovation and collaborative mindset. With its state-of-the-art infrastructure and close ties with industry partners, EPFL plays a key role in the development of advanced technological solutions, ranging from artificial intelligence to biotechnology, sustainable energy, and robotics.



UNIVERSITÉ DE GENÈVE

The University of Geneva (UNIGE) is a renowned academic institution, recognized for the excellence of its teaching and research in a wide range of disciplines, from natural and medical sciences to humanities and social sciences. Founded in 1559, it has a long history of being a key player on the international academic scene, working closely with local, governmental and international organizations, particularly those based in Geneva, such as the UN and WHO. With its strong roots in a globally open city, UNIGE fosters a stimulating intellectual environment conducive to innovation and critical thinking. Its commitment to sustainable development, diversity, and interdisciplinarity makes it a center of academic excellence at the service of society.



The Geneva University Hospitals (HUG) are one of Switzerland's leading hospital centers and a center of excellence in healthcare, teaching, and clinical and translational research. Associated with the University of Geneva's Faculty of Medicine, the HUG offers cutting-edge expertise in many fields, ranging from precision medicine to transplantation, neuroscience, and oncology. Thanks to the hospital's modern infrastructure and commitment to innovation, the HUG actively contribute to the advancement of medical knowledge and the continuous improvement of continuous improvement of care practices. The mission of HUG is based on a patient-centered approach, ensuring high-quality care while contributing to the training of the next generation of healthcare professionals.

OUR PARTNERS



The Wyss Center for Bio- and Neuroengineering is a translational research institute dedicated to advancing neurotechnology and biomedical solutions. By combining expertise in neuroscience, artificial intelligence, and biomedical engineering, it develops innovative technologies to improve diagnosis, treatment, and quality of life for patients with neurological disorders. Through an interdisciplinary approach and state-of-the-art infrastructure, the Wyss Center accelerates the transition from scientific discoveries to clinical applications, in collaboration with researchers, academic institutions, and industrial partners. Its commitment to innovation and top-tier research makes it a major player in the field of neurotechnology.

h e p i a

Haute école du paysage, d'ingénierie
et d'architecture de Genève

The Haute école du paysage, d'ingénierie et d'architecture de Genève (HEPIA) is an educational and applied research institution that plays a key role in developing modern and flexible solutions for engineering, architecture, and landscape management. As part of the network of universities of applied sciences in Western Switzerland (HES-SO), HEPIA offers courses addressing real-life needs with close links to the professional world, thereby promoting the employability of its graduates. Through its laboratories and collaborations with industry and local authorities, it actively contributes to implementation of ecological transition, sustainable technologies and smart urban planning. With its interdisciplinary approach and local roots, HEPIA is a key player in sustainable development, urban and landscape planning in the Lake Geneva area.

Governance

The Foundation Board is the supreme governing body of the FCBG. It is composed of representatives from the UNIGE, EPFL, the Canton of Geneva, and the HUG.

The FCBG's Director General participates in meetings in an advisory capacity.

Members of the Foundation Board as of January 1, 2025:

President	Prof. Audrey Leuba, Rector of UNIGE
Vice-President	Prof. Anna Fontcuberta i Morral, President of EPFL
	M. Robert Mardini, Chief Executive Officer of the HUG
	M. Daniel Loeffler, Deputy Secretary General DEE, Canton of Geneva

Members of the Bureau of the Foundation Board as of January 1, 2025:

Coordinator	Dr. Nicolas Durand, Chief Executive Officer, FCBG
	M. Lionel Cau, Director of Operations, UNIGE Campus Biotech
	Dr. Danielle Desravines, Director of Operations, EPFL Geneva
	Prof. Antoine Geissbuhler, Dean of the Faculty of Medicine, HUG
	Prof. Stéphanie Lacour, President of the Academic Council 2025

Retrospective

2014

Launch of the Human Brain Project

2016

Installation of HEPIA laboratories, inauguration of the Campus Biotech Innovation Park

2018

Campus Biotech becomes a key player in the Swiss Innovation Park (SIP WEST EPFL)

2013


Creation of the FCBG by EPFL and UNIGE. Arrival of the first research group (CISA).

2015

The HUG joins the FCBG, official inauguration of the Campus Biotech, rollout of the first neuroscience platforms

2017

Launch of the Genome Center





2020

Obtained a donation of CHF 20 million to purchase state-of-the-art functional imaging equipment (MEG & 7T MRI).

2022

Establishment of first MEG in Switzerland, installation of the 7T MRI scanner

2024

Development of clinical activity on most platforms, launch of an outpatient clinic for the HUG

2019




Launch of gene therapy platform

2021

Obtained a donation of CHF 36 million to set up an organoid platform

2023

Partnership established with FONGIT





A NEW DYNAMIC FOR THE FOUNDATION CAMPUS BIOTECH GENEVA

Dr. Nicolas Durand (CEO), Ms. Isabelle Jeanclaude (HR & Facility Manager), Dr. Olivier Reynaud (Platforms Manager), and Ms. Sara Llorca (CFO)

Management Team

The year 2024 marks a major turning point for FCBG with the arrival of a new management team led by its Director, Dr. Nicolas Durand. Upon taking office, he assembled a close-knit and complementary team, bringing together Sara Llorca (Chief Financial Officer), Dr. Olivier Reynaud (Platforms Manager), and Isabelle Jeanclaude (HR and Infrastructure Manager).


Under their leadership, the Foundation has embarked on an in-depth review of its operating methods with a view to optimizing its resources and enhancing effectiveness. One of the first tasks for the new management team was to conduct comprehensive audits of all FCBG departments to identify strengths and areas for improvement in the organization and management of platforms, infrastructure, and finances.

Results of these analyses led to major strategic decisions to reduce costs, optimize the services offered to researchers, and strengthen the Foundation's scientific impact. Accordingly, adjustments were made to the management of technology platforms and services, ensuring more agile and sustainable operations.

Thanks to the renewed and pragmatic vision, the FCBG is entering a new phase of development, where scientific excellence and innovation remain at the heart of its missions, while structured operational framework ensures more efficient and sustainable management.

« **Scientific excellence and innovation can only flourish within a well-structured framework. In 2024, our priority was to strengthen the foundations of the FCBG so that it can be more agile, more efficient, and ever more ambitious in its missions.** »

Dr. Nicolas Durand, Chief Executive Officer, FCBG




Academic Council

A NEW ACADEMIC COUNCIL TO GUIDE THE FCBG'S SCIENTIFIC STRATEGY

In 2024, the FCBG reached a new milestone in its development with the establishment of its Academic Council, a strategic body designed to strengthen the scientific and technological strategy of the Campus.

Chaired in 2024 by Prof. Antoine Geissbuhler (HUG), this Council brings together recognized experts in their fields: Prof. Stéphanie Lacour (EPFL), Prof. David Sander (UNIGE) and Prof. Erwin Böttinger (Wyss Center for Bio- and Neuro-engineering, with an advisory role). The FCBG's Director General, Dr. Nicolas Durand, also participates in an advisory capacity, ensuring consistency between the Foundation's scientific vision and operational management.

The Council also benefits from the expertise of invited members, including Prof. Camilla Bellone (UNIGE) and Prof. Olaf Blanke (EPFL), who contribute insights from the fields of digital health, neuroscience and neuro-technology to the major developments.

 Prof. Olaf Blanke, Prof. Stéphanie Lacour, Prof. David Sander, Prof. Camilla Bellone and Prof. Antoine Geissbuhler

Since its launch, the Council has played a central role in defining the priority areas for research and development for the Campus, ensuring increasingly close collaboration between partner academic institutions and FCBG infrastructures.

The key objectives of the Council are to guide strategic investments, evaluate the evolution of technology platforms, and guarantee scientific excellence within Campus Biotech.

With this new academic governance structure, the FCBG has established a solid framework for anticipating its academic partners research needs, promoting interdisciplinary collaboration, and keeping Campus Biotech at the forefront of scientific and medical innovation.

« To ensure that Campus Biotech remains a driving force in neuroscience and digital health innovation, it is essential to build a strong, shared, and forward-looking scientific vision. The Academic Council is here to guide this ambition. »

**Prof. Antoine Geissbuhler,
President of the Academic Council 2024, FCBG**



Platform Advisory Committees (PACs)

In 2024, decision was made that each FCBG platform would have its own Platform Advisory Committee (PAC), a scientific committee created to provide each platform with specific academic insight. Composed of key members of the community (appointed by the Academic Council) and the platform manager, the PAC meets monthly to provide scientific and technological expertise.

The PACs are responsible for identifying and prioritizing the needs of their respective platforms, particularly regarding equipment renewal, and defining a development strategy.

Introduction of PACs stimulates synergies within the scientific community and promotes platforms both internally and externally.

For all strategic and budgetary decisions, the PACs submit their recommendations to the Academic Council and, if necessary, to the Management and Foundation Board. These committees, jointly coordinated by the Platforms Manager, Dr. Olivier Reynaud, and the managers of each platform, thus play a central role in the development and optimization of the FCBG platforms.



Academic members of the Magnetic Resonance Imaging Platform (MRI) PAC:

Prof. Frédéric Grouiller	UNIGE/CIBM
Prof. Patrik Vuilleumier	UNIGE/CIBM
Prof. Valentina Borghesani	UNIGE
Prof. Olaf Blanke	EPFL
Prof. Dimitri Van De Ville	EPFL/CIBM
Prof. Andreas Kleinschmidt	HUG
Prof. Jean-Paul Vallée	HUG/CIBM
Prof. Karl-Olof Lovblad	HUG
Prof. Dimitrios Karampinos	EPFL/CIBM

Academic members of the Magneto-, Electro-Encephalography and Neuromodulation Platform (MEG) PAC:

Prof. Friedhelm Hummel	EPFL
Prof. Alexis Hervais-Adelman	UNIGE
Prof. Adrian Guggisberg	HUG

Academic members of the Preclinical Neuroscience Platform (PNP) PAC:

Prof. Grégoire Courtine	EPFL
Prof. Denis Jabaudon	UNIGE
Dr. Bernard Schneider	EPFL

Academic members of the Virtual Reality and Digital Engineering Platform (VRD) PAC:

Prof. Alexander Mathis	EPFL
Prof. Daphne Bavelier	UNIGE

Academic members of the Human Cellular Neuroscience Platform (HCNP) PAC:

Prof. Pierre Magistretti	EPFL
Prof. Fides Zenk	EPFL
Prof. Denis Jabaudon	UNIGE

Academic members of the Neural Microsystems Platform (NMP) PAC:

Prof. Stéphanie Lacour	EPFL
Dr. Didier Ferrere	UNIGE

Academic members of the Clinical and Sleep Research Platform (CSR) PAC:

Prof. Friedhelm Hummel	EPFL
Prof. Sophie Schwartz	UNIGE
Prof. Indrit Bègue	HUG



FCBG partners

STRATEGIC PARTNERSHIPS FOR INNOVATION EXCELLENCE

Since its inception, the FCBG has been built on a unique collaborative model, bringing together academic institutions, hospitals, research centers, and industry players. In 2024, these partnerships continued to intensify, strengthening the FCBG's role as a convergence platform for translational research and technological innovation.


The FCBG would like to express its deep gratitude to its partners and donors for their commitment and trust, which make our training and innovation activities possible. Some have been with us since the foundation was established, and we sincerely thank them for their loyalty.



OTHER ENTITIES PRESENT ON THE CAMPUS BIOTECH SITE

The Campus Biotech, alongside the FCBG, is home to a dynamic ecosystem bringing together academic, clinical, industrial, and institutional players. They collaborate and and share the Campus ecosystem with start-ups, innovative companies, and international organizations, creating an environment conducive to innovation, interdisciplinary research, and technology transfer.

Access Accelerated	Aga Khan Development Network	Agora Care	Amazentis
André Roland	ARB Biotech	Artiria Medical	Biostime Institute for Nutrition and Care
BioXpress Therapeutics	Bridges to development	BrainQuant	BrainScape
CEDAM	Climb Ventures	Concept Foundation	Cosmovici Intellectual Property
CyberPeace Institute	DBS System	Dandelion Science	DataFlight Solutions
dEEGtal	DiaAlza	DONA Fondation	Dure Technologies
Earlysight	Ebamed	EspeRare	Forethought Access
Genegis BioLab	Gliapharm	Goodwall	HC2 Health Care
High Lantern Group	HMCare	IFPMA - International Federation of Pharmaceutical Manufactures & Associations	
IMSG - International Management School Geneva		Incite Medical Eng	lot Lab
Ionctura	iRhythm	ISA-Lex Avocats	MedC Partners
Centre Synapsy (NCCR Synapsy)	Neurosoft Bioelectronics	Neurosterix / Addex	Octave Biotech
OneDoc	Orion Biotechnology Switzerland	Phasis	Regdata
Release Therapeutics (MaxiVax)	Relief Therapeutics	Rodanotech	SCIENTIS
Stalicia	Trust Village	Wecan Group	World Connect



Magnetic Resonance Imaging (MRI) platform

PRESENTATION

MRI is an essential tool for neuroscience research, enabling non-invasive imaging of brain anatomy, function, and connectivity with millimeter precision. Managed by Dr. Roberto Martuzzi, the Magnetic Resonance Imaging platform (MRI) specializes in high-risk, high-impact MRI studies, integrating advanced technological, methodological, and analytical components.

KEY FEATURES


The MRI platform houses one of the few latest-generation 7 Tesla MRI scanners in Europe, enabling cutting-edge research in the fields of technical development, neuroscience, and clinical research. The platform integrates MRI data with EEG, virtual reality, non-invasive electrical stimulation, and biomarker analysis, thereby maximizing research potential.



Key equipment

Siemens Healthineers MAGNETOM Prisma 3T MRI

Siemens Healthineers MAGNETOM Terra.X 7T MRI

Motion capture, virtual reality, and non-invasive brain stimulation systems compatible with 3T MRI





KEY FIGURES FOR 2024

1st

Siemens Healthineers MAGNETOM Terra.X scanner in the world

24

peer-reviewed publications in 2024 (scientific journals)

Over 2,400 hours

of research projects

2 days/week

of clinical activity in ultra-high field MRI supported by the HUG

Outlook




The platform aims to strengthen its collaboration with other platforms and improve the integration of EEG, VR, and neuromodulation technologies with 3T and 7T MRI.

Highlights in 2024

- The MRI platform became independent following the reorganization of the Human Neuroscience platform. The MRI PAC was expanded to include more diverse expertise.
- The 7 Tesla MRI scanner was upgraded to the latest generation Siemens Healthineers MAGNETOM Terra.X model, incorporating AI-assisted image reconstruction for improved accuracy and resolution.
- The use of the 7 Tesla MRI scanner has increased significantly, thanks to partnerships with the HUG Diagnostic Department for clinical activity and with the Center for Biomedical Imaging (CIBM) for research studies.

« The FCBG MRI platform promotes close collaboration, particularly with the HUG and the CIBM, by utilizing complementary MRI equipment, including the 7 Tesla MRI scanner, to advance clinical and translational research. These partnerships, along with strong synergies with other local platforms, accelerate innovation and strengthen patient-centered research. »

Prof. Frédéric Grouiller,
Head of the CIBM-HUG MRI department and President of the MRI PAC




M/EEG & Neuromod (MEG) platform

PRESENTATION

Managed by Dr. Gwénaél Birot, the M/EEG & Neuromod platform provides researchers with equipment and expertise in electroencephalography (EEG), magnetoencephalography (MEG), and neuromodulation. EEG and MEG are key neuroimaging techniques that allow brain activity to be monitored on a millisecond scale, making them ideal for studying rapid brain processes. Neuromodulation uses electrical (TES) or magnetic (TMS) stimulation to non-invasively modulate brain activity, particularly in psychiatry to study and treat disorders such as depression and schizophrenia.

KEY FEATURES

- The only MEG system in Switzerland
- Multimodal integration with other platforms:
 - Simultaneous TMS/fMRI, TACS/fMRI, EEG/VR, and EEG/Neuromodulation
- Expertise in real-time EEG for brain-computer interface (BCI) and neurofeedback protocols



KEY FIGURES FOR 2024

Key equipment

MEGIN Triux neo MEG system

7 EEG systems

ultra-high density headbands

3 TES systems

compatible with MRI and EEG

3 TMS systems,

including TMS-MRI and rTMS for treatments

8

experimental cabins

Physiological recording devices
(eye tracking, respiration, heart rate, etc.)

+10,000 hours

of equipment use

12 peer-reviewed

publications in 2024
(scientific journals)

66 projects

from 35 research groups and 6+
academic partners



Highlights in 2024


- Merger of EEG-BCI, MEG, and Neuromodulation facilities to form the M/EEG-Neuromod platform
- Creation of a user wiki for MEG, EEG, and neuromodulation equipment
- Development of community data processing software (MNE-python)

Outlook

The platform plans to adopt and integrate new technologies such as temporal interference stimulation, ultrasound, OPM-MEG, and robotic TMS for increased accuracy. It also aims to expand its services to international researchers and private companies.

« The FCBG's MEEG-NMOD platform offers exceptional infrastructure and active practical support for cognitive neuroscience research requiring cutting-edge techniques. Thanks to the platform team, we can launch studies efficiently and effectively, even for complex projects involving multiple phases and instruments. »

Prof. Alexis Hervais-Adelman,
Faculty of Medicine, University of Geneva, and member of the MEG PAC



Preclinical Neuroscience Platform (PNP)

PRESENTATION

Founded in 2016, the Preclinical Neuroscience Platform (PNP) offers a wide range of in vivo and ex vivo services and benefits from the dynamic research environment provided by the Campus Biotech. The platform provides efficient facilities, appropriate equipment, and adequate support dedicated to neuroscience and neurodevice research on rodent models. Approximately 2,000m², spread over three floors, are dedicated to neuroscience research, with a dedicated team of eight professionals supporting the research teams.

The platform is divided into two main areas :

- Experimental areas (operating rooms and experimental rooms).
- Laboratories, offering three facilities for the preparation, processing, and analysis of tissues or cells. The laboratories have areas dedicated to histology, molecular biology, and cell culture.

KEY FEATURES

- State-of-the-art infrastructure and shared spaces equipped with key scientific tools.
- Preclinical studies and ex vivo analyses within a single platform.
- Support for researchers by a dedicated support team.

Highlights in 2024

- Relocation of laboratories and expansion of experimental areas.
- Arrival of a new animal caretaker to meet growing needs.
- Development of cell culture and molecular biology services.
- Arrival of Prof. Denis Jabaudon (UNIGE) at Campus Biotech and integration into the PNP PAC.

Outlook

Expansion of experimentation and histology services to better support researchers.

Active support for the Lighthouse Project led by the Wyss Center, notably in collaboration with EPFL, UNIGE, and HUG. This project aims to develop new technologies to treat neurological and mental health disorders through AI-guided neuromodulation.

« The FCBG's scientific platforms offer efficient services and access to cutting-edge technologies enabling innovative research in translational neuroscience. The collaborative environment of the Campus Biotech platforms provides researchers with shared resources that accelerate scientific advances and innovation. We are extremely grateful for this support, which plays a crucial role in the scientific progress of our laboratories. »

Dr. Bernard Schneider,
Head of the
Bertarelli Gene Therapy Platform (EPFL)

KEY FIGURES FOR 2024

PNP surface

1,870 m²

experimental areas : 1,640 m²,

laboratories : 230 m²

11 research groups

and over 100 users

130

major pieces of equipment

20 publications

including several studies in prestigious scientific journal :

- Skinnider et al (Nature, 2024). Single-cell and spatial atlas of spinal cord injury in the Tabulae Paralytica project.
- Cho et al (Nature Medicine, 2024). Deep brain stimulation of the hypothalamus improves walking after spinal cord injury.
- Ye et al (Nature Communications, 2024). Pre-trained SuperAnimal models for posture estimation in behavioral analysis.
- Moritz et al (Nature Medicine, 2024). Non-invasive electrical stimulation of the spinal cord to improve arm and hand function in chronic quadriplegia: a safety and efficacy trial.



Virtual Reality and Digital Engineering Platform (VRD)



PRESENTATION

Virtual reality (VR) technology provides researchers with a powerful tool for conducting realistic, safe, and reproducible experiments. It combines perfectly with technologies such as EEG and functional MRI for multimodal studies. Led by Margaux Dubessy, the Virtual Reality and Digital Engineering platform (VRD) team supports researchers by co-creating immersive content, interactive scenarios, and 3D applications. A growing library of software and configurations accelerates development and enables on-demand demonstrations. Innovative projects are developed in collaboration with research laboratories, benefiting both individual teams and the wider scientific community.

KEY FEATURES

- The team members have a wide range of skills, including XR development (virtual, augmented, and mixed reality) on different platforms (Windows, Mac, Linux, Android, iPhone), as well as motion capture and the use of various sensors.
- Collaboration with other platforms facilitates the implementation of multidisciplinary projects integrating brain imaging technologies (MRI, EEG, MEG, etc.).
- Interaction and proximity with scientists, professors, and students enable us to quickly understand the specific needs and challenges of each study.

Highlights in 2024

- Creation of a basic application for a virtual reality experience in MRI, with reproduction of a real MRI environment in the virtual world and the ability to view and move an avatar's body in real time
- Functional application deployment platform: Steam, Play Store (Android)
- and Apple Store (iOS) Improvement of eye-tracking tools integrated into applications

KEY FIGURES AND PROJECTS IN 2024

Expansion of the application catalog to
34 delivered projects


3 peer-reviewed publications
in 2024 (scientific journals)

8 projects developed
during the year, including:

Woundcare is an educational mobile app developed by the VRD platform with Unity in collaboration with Prof. Swann Pichon (HES) and the company Imito, thanks to funding from Innosuisse. This serious game, tested at the HUG, enables healthcare professionals to strengthen their skills in wound assessment and management through interactive activities and progressive challenges. By collecting points, players contribute to the construction of a virtual clinic dedicated to wound care.



Drawing and Detective is a series of games developed for the virtual reality room at the QAP Center in Carouge, a rehabilitation center for children with disabilities. Used by physical therapists, these interactive games are projected onto a 2x3m wall via a motion capture system, motivating children to get moving while having fun. Drawing allows children to paint and create freely, while Detective challenges them to find hidden objects in a street, with adjustable difficulty levels.



Outlook


- Integration of Artificial Intelligence in virtual content creation
- Development of virtual reality tools compatible with 7 Tesla ultra-high field MRI

« Virtual reality is a fantastic tool for understanding human behavior, from perception to memory. »

Prof. Alexander Mathis, EPFL

« The Virtual Reality and Digital Engineering platform enables the creation of experiences that are closer to everyday reality, while providing accurate measurements of brain function, a crucial advance in our understanding of the brain and behavior. »

Prof. Daphné Bavelier, UNIGE



Neurona Human Cellular Neuroscience Platform (HCNP)



PRESENTATION

Led by Dr. Théo Ribierre and funded by the Geneva-based NeuroNA Foundation, the Human Cellular Neuroscience Platform (HCNP) stands out for its unique mission and capabilities. It provides state-of-the-art equipment for the culture, genome editing, and differentiation of human brain organoids in 3D, as well as for the collection, handling, and biobanking of human brain samples. Advanced analytical tools enable multimodal characterization of human samples (genetic, transcriptomic, microscopy, and electrophysiology).

The HCNP offers its services to the academic and business communities and assists researchers in drafting funding applications and ethical protocols for biobanks. The infrastructure has been awarded NORMA certification by the Swiss Biobanking Platform.

« Platforms play a key role in advancing our science. From cellular neuroscience to human imaging, a wide range of equipment is available. The equipment is important, but it is worthless without the expertise to go with it. This expertise is also available on site, enabling us to anticipate and make the right decisions. »

Prof. Denis Jabaudon, UNIGE



KEY FIGURES

26

projects in progress.

2 grants

obtained as co-investigator.

2 scientific publications

Key equipment

Vizgen MERSCOPE
spatial transcriptomics

Nikon AXR
confocal microscope with
incubation chamber

10X Genomics
Chromium X
microfluidic device for
high-throughput single-cell
transcriptomics

3Brain HYPERCAM
Alpha
high-density electrophysiological
measurements

Becton Dickinson
FACS Melody
cell sorting device

Specialized equipment for stem
cell culture, tissue preparation,
molecular biology, and biobanking

KEY FEATURES

- State-of-the-art equipment to conduct innovative research projects in human cellular neuroscience, from cell culture to final analysis.
- Dedicated staff providing expertise in each key technique, with support ranging from project writing to molecular biology, cell reprogramming, cell cultures, microscopy, and biobanking.
- Customized services, with priority given to academic laboratories.

Highlights in 2024


- Opening of two new facilities :
 - Preparation, microdissection, and culture of primary tissues.
 - Nucleic acid extraction and pre-amplification for high-throughput transcriptomics.
- Development of new approaches to handling primary human tissue.
- Organization of the NeuroNA Human Cellular Neuroscience Symposium (200 participants, Campus Biotech).
- Winner of the Uygtsensu-Hamilton 22q11 Neuropsychiatry Research Prize (USD 300,000).
- Awarded the "Certified Service Provider" label in spatial transcriptomics (Vizgen, MERSCOPE platform).
- Appointment of Dr. Théo Ribierre to the scientific advisory board of the stem cell and organoid platform at the Faculty of Biology and Medicine at UNIL.

Outlook

- Exploration of robotic automation for lengthy experimental stages.
- Creation of an integrated preclinical technology center dedicated to human cellular neuroscience, offering customized services in genetics, transcriptomics, and electrophysiology on brain models derived from human tissue.



Neural Micro-Systems Platform (NMP)



PRESENTATION

Created in 2015 within the Wyss Center and transferred to the FCBG in 2021, the Neural Micro-Systems Platform (NMP) specializes in the development of portable and implantable neurotechnologies. Managed by Michaël Stoeckel, the NMP has a cleanroom of approximately 120m². The platform brings together experts in engineering, life sciences, and medical sciences to design advanced neurotechnology solutions. The NMP focuses on improving biointegration, bidirectional modalities, and the spatio-temporal resolution of devices, thereby addressing challenges related to clinical demonstration and large-scale manufacturing.

KEY FEATURES

The NMP excels in the development of portable and implantable devices offering better biointegration and excellent performance. While many innovations target neuroscience research (e.g., conformal epiretinal implants, e-dura, flexible ECoGs), few reach medical applications; The NMP fills this gap by supporting clinical demonstration.

Highlights of 2024

- Replacement of the MJB4 mask aligner with an MA6, offering better resolution and improved dorsal alignment.
- Major result: Neurosoft ECoG electrodes were tested in an initial clinical study involving three participants.
- CERN has become a regular user of the NMP.
- Production of electrodes as part of the Wyss Center's Neuro GI project.



KEY FIGURES

Key equipment

120 m² cleanroom
(ISO7, class 10,000)

Laser micromachining,
Heidelberg mask-less aligner,
Alliance Concept Sputter and
Evaporator, Corial Etcher, Hitachi
environmental SEM, Nanolabb

4 peer-reviewed publications

in 2024 (scientific journals), including the
following high-impact studies

Mariello et al. (Nature Communications)
– Wireless, battery-free monitoring of
water permeation along encapsulated
thin layers

Paggi et al. (Bioelectronic Medicine)
– Development of a multi-contact
electrode for nerve modulation

Martinelli et al. (Science Advances)
– Development of a brand new electrode
system for 3D electrophysiology
measurements


Wu et al. (Advanced Materials)
– Optical monitoring of water permeation
during thin film encapsulation

Outlook

- Acquisition of CXC-20 multi-layer deposition equipment in mid-2025
- Optimization of the cleanroom, particularly in the PDMS area, to accommodate this new equipment
- Expansion of cleanroom facilities to integrate medical-grade materials and processes

« The Neural Micro-Systems Platform (NMP) offers a unique environment where microfabrication, thin film technology, and neural implant development intersect, bridging fundamental research and translational manufacturing. With its expertise in polymer-based microfabrication, the NMP enables new approaches to neural interface design, supporting both scientific exploration and technological advancement in neurotechnology. »

Prof. Stéphanie Lacour (EPFL),
President of the Academic Council 2025 and member
of the PAC of the NMP



Clinical and Sleep Research Platform (CSR)


PRESENTATION

Co-managed by Dr. Virginie Sterpenich and Dr. Kinga Igloi, the clinical and sleep research platform (CSR) offers private rooms for behavioral testing, neuropsychological interviews, and clinical assessments, ensuring a confidential environment for healthy volunteers and patients. It also includes a P2 biological laboratory for the analysis of blood and saliva biomarker samples. In close collaboration with the HUG, it integrates outpatient care using a dedicated digital infrastructure, including eight clinical interview rooms and two specialized rooms equipped with synchronized cameras for the analysis of psychiatric and neurological disorders. Medical assistance and a blood sampling service are available on site. A range of neurological tests is also available for children and adults.

In addition, the platform supports sleep research with three bedrooms located near the MRI facilities, enabling multidisciplinary studies of brain function before, during, and after sleep, including polysomnography with EEG. The biomarker service also supports researchers by advising on study design, managing data and financial aspects, preparing and analyzing samples, and integrating multimodal data from various neuroimaging techniques.

KEY FEATURES

- The only sleep research platform in French-speaking Switzerland, distinguished by its multimodal and cross-platform approach.
- Unique opportunities to accommodate patients on site in three individual rooms equipped with EEG equipment and olfactory stimuli.
- A synchronized camera system is available to diagnose and decode certain psychiatric disorders using artificial intelligence.



Highlights in 2024

- Official launch of blood and saliva biomarker measurement service
- Inauguration of the HUG Neurocenter outpatient clinic in fall 2024 (pilot phase)

Outlook

- Strengthening clinical activity at the Campus Bio-tech site.
- Developing biomarker analyses in collaboration with the Genome Center and the HCNP.
- Redesigning the sleep laboratory to enable several studies to be conducted simultaneously.

KEY FIGURES

30

research projects

+100

polysomnographic recordings
corresponding to

+1,700 hours

of use

+3,400 hours


of behavioral experience

5 peer-reviewed
publications

in 2024 (scientific journals)

- « The Clinical and Sleep Research Platform provides exceptional support for clinical research and fundamental studies in neuroscience. It manages sleep monitoring, comprehensive clinical assessments with extensive video recordings, and biomarker analysis. With its state-of-the-art equipment and expert staff, it ensures the smooth execution of projects, including randomized clinical trials. »

Prof. Indrit Bègue, HUG



Health 2030 Genome Center (GC)

PRESENTATION


Created in 2017 by the Health 2030 initiative, the Genome Center (GC) promotes genomic research and medicine in Switzerland. The GC offers genomic data generation, analysis, and management services to the Swiss research and clinical community. Since 2022, it has played a key role in national initiatives such as the Swiss Personalized Health Network (SPHN) and the ETH Personalized Health and Related Technologies (PHRT) programs. The Genome Center comprises two platforms: the DNA sequencing platform (DSP) and the data analysis and interpretation platform (DAIP).

KEY FEATURES

The Genome Center offers ISO 15189-accredited clinical-grade services, ensuring reliable data for healthcare. It stands out for its expertise in large-scale genomic projects, providing rapid information for intensive care, precision oncology, and population genomics.

Highlights in 2024

- ISO 15189 accreditation for WGS (Whole Genome Sequencing), WES (Whole Exome Sequencing) and RNA-seq services
- Expansion of services for clinical and population genomics
- Major role in the National SARS-CoV-2 Surveillance Program
- Designation as a center of expertise in genomics for the Swiss Federated Genomics Network project
- Contribution to the SPHN/PHRT Genome of Switzerland pilot project
- Acquisition of liquid handling robots for WGS sample preparation



Outlook

- Integration of new emerging sequencing technologies
- Expansion of respiratory virus detection for public health surveillance
- Combined genome-exome sequencing for improved risk assessment
- Population-scale WGS sequencing for genotyping (in collaboration with CHUV)
- Expansion of the Genome of Switzerland project to 15,000 samples
- Improvement of IT infrastructure to support genomic medicine in western Switzerland

« At the Genome Center, we have taken on the responsibility of providing personalized healthcare to Swiss citizens through national initiatives in genomics and in collaboration with the Genome of Europe project. »

Prof. Alexandre Reymond, Director of the Genome Center since November 2024
and professor of Human Genetics at the University of Lausanne



HUG Outpatient Neuroclinic

ADVANCING BRAIN HEALTH THROUGH INNOVATION

In 2024, the Neurocenter of the Geneva University Hospitals (HUG) opened its first outpatient clinic for brain and mental health at the Campus Biotech. This project is being carried out in collaboration with the Departments of Clinical Neuroscience and Psychiatry, headed by Prof. Karl Schaller and Prof. Stefan Kaiser, respectively.



NEUROCENTRE



This initiative illustrates the HUG's commitment to improving care and stimulating innovation in neurological diseases, neurotrauma, and brain health.



<https://www.hug.ch/en/neurocentre/outpatient-clinic-brain-and-mental-health>

The clinic initially focuses on cognitive and motivational deficits, which are very common in traumatic brain injury and psychiatric disorders. By integrating the latest advances in research, innovation, and patient care, this platform aims to improve outcomes for people facing complex brain health challenges. It pro-

motes synergies between research and clinical care, accelerating the transformation of scientific discoveries into optimized therapeutic strategies.



ACTIVITIES


This state-of-the-art facility, set to open in the second half of 2024, is located at the entrance to the neuroscience area of the Campus Biotech. Neurological, neuropsychological, psychiatric, and neurosurgical examinations are carried out on site by HUG doctors in recently renovated consultation rooms. These assessments are often supplemented by MRI scans performed on nearby imaging platforms, including the latest-generation 7 Tesla MRI scanner, which offers an unprecedented level of cerebral detail for the Geneva clinical population.

The primary goal of this multidisciplinary consultation unit is to provide specialized follow-up care for patients with persistent cognitive and motivational deficits.

Already incorporating its initial research projects, the HUG outpatient clinic launched an innovative clinical trial based in Geneva aimed at improving negative social symptoms in psychiatric patients. This study, which was awarded the Leenards Foundation Prize in 2023, applies the latest advances in neurotechnology and non-invasive brain stimulation, offering direct benefits for patients' comfort and quality of life.

IMPACT AND VISION

This initiative expands access to clinical care while advancing translational research in neurotechnology, cognitive science, and therapies developed at Campus Biotech. The outpatient clinic strengthens Geneva's position as a global leader in neuroscience and health-care innovation by fostering collaboration between researchers, clinicians, and technology experts to improve patient outcomes.



Our services



SERVICES DEDICATED TO A DYNAMIC AND INNOVATIVE COMMUNITY

The FCBG provides its researchers, staff, and partners with a comprehensive range of services designed to facilitate scientific work, encourage innovation, and improve well-being on campus. In 2024, these services were optimized to meet the real-life needs of users and enhance quality of work environment.

EVENTS: A MEETING PLACE FOR SCIENCE AND INNOVATION

On top of infrastructure, Campus Biotech offers grounds for exchange and collaboration, hosting more than 150 scientific, academic, and industrial events each year. Conferences, workshops, seminars, and hackathons are organized to promote dialogue between researchers, startups, and companies. Modern facilities in the Campus—conference rooms, an amphitheater, and reception areas—make organization easy, ensuring a setting that supports sharing ideas, knowledge and scientific advances.

FCBG SUPPORT TO THE «CÉLÉBRALES» EVENT ORGANIZED BY THE SYNAPSY CENTER

The FCBG was delighted to be involved in organizing the Célébrales event at the Synapsy Center of the University of Geneva, a festival dedicated to discovering neuroscience and raising public awareness of scientific advances in brain research. The event took place on Saturday, October 5, 2024, at the Bâtiment des Forces Motrices in Geneva.

This partnership aligns and complements the FCBG mission to promote dissemination of knowledge and encourage exchanges between researchers, health-care professionals, and citizens. By providing logistical and technical support to the event, the Foundation helped to make it a success.

Les Célébrales provided a unique platform for exchange, where the public could interact with experts, discover innovative research projects, and gain a better understanding different aspects related to neurodevelopmental and psychiatric disorders. The program included :

■ **Conferences:** Scientific presentations by internationally renowned specialists and testimonials from people affected by mental disorders shed light on the links between neuroscience, psychiatry, and patient stories. For example, Professor Marie Schaer discussed technological and scientific advances toward early detection and diagnosis of autism spectrum disorders. Professors Valérie Schwitzgebel and Christian Lüscher, meanwhile, introduced the biological basis and clinical aspects of eating disorders.

■ **Round table:** An interactive session brought together neuroscientists, artists, and psychiatrists to demystify the complexity of the brain and mental disorders. Professors Camilla Bellone, Denis Jabaudon, and Stefan Kaiser contributed their expertise in neuroscience and psychiatry, while comedians Brigitte Rosset and Thomas Wiesel shared their personal experiences with mental disorders, adding a touch of humor to the discussion on this serious public health issue.



■ **Educational workshops:** Led by FCBG staff members, among others, workshops gave the public an opportunity to learn about and experience mental health in a fun way. Topics included consciousness, neuroanatomy, bio- and neurofeedback, autism spectrum disorders, borderline personality disorder, psychedelics, virtual reality, neuroinvestigation tools, and microscope observation.

By supporting events such as Les Célébrales, the FCBG continues to support scientific outreach and dialogue between science and society. This type of initiative raises awareness of advances in neuroscience and promotes public interest in the challenges and opportunities associated with understanding the human brain.



Information Technology (IT): cutting-edge technological support

The FCBG IT service provides a reliable, high-performance, and secure infrastructure. It guarantees user access to the digital tools needed for research projects, offers technical support, and ensures data protection. Network modernization and a new document management system were implemented in 2024 to support the growth of scientific platforms and strengthen cybersecurity.

Mechanical workshop: from idea to completion

The FCBG mechanical workshop offers a manufacturing and machining space for the design of prototypes and research devices. Researchers and engineers can use the equipment, such as milling machines, lathes, laser cutting, etc., to design and refine their projects with the support of mechanical engineering experts. This service plays an important complementary role in the development of measurement benches for various research projects.



3D printing and prototyping: accelerating innovative solutions

In collaboration with HEPIA, the design and manufacturing service offers access to 3D printing and rapid prototyping, enabling researchers and entrepreneurs to quickly bring their ideas to life. FCBG has a set of 3D printers suitable for working with various materials (plastic, resin, metal) to produce models, experimental devices, and functional prototypes.

Daycare: balancing work and family life

To support researchers and employees with children, a modern and welcoming daycare center is available on the Campus Biotech site. It offers a safe and stimulating environment for children, with hours tailored to the needs of parents working in the Campus or nearby. The daycare service helps our employees to balance their personal and professional life and increases potential of the Campus to attract and retain talented staff.



Fitness: a healthy mind in a healthy body

Employee well-being is a priority for FCBG. The fitness center offers a range of equipment to promote health and performance. Whether for a quick workout or a more intense session, this space contributes to the quality of life on site and encourages a balanced approach to work and physical well-being.



Infrastructure management: ensuring welcoming work environment

The infrastructure management service ensures the smooth running and maintenance of Campus Biotech's buildings, laboratories, and common areas. It provides efficient management of resources, energy, and technical equipment, guaranteeing a safe and well-planned working environment for researchers and companies. In 2024, several improvements were implemented to optimize energy consumption and to reduce carbon footprint on site.


Infirmiry: fast and efficient care

The Campus Biotech infirmiry provides rapid medical care for employees and visitors. Whether for first aid, health advice, or minor emergency management, this service ensures a safer and more peaceful working environment.



Catering: a new catering service with Newrest

In 2024, Campus Biotech welcomed Newrest as the new catering partner, offering a renewed and high-quality culinary experience. Every day, several delicious dishes of the day are available, using fresh, local responsibly produced ingredients. With a varied and balanced menu compatible with different dietary preferences and needs, Newrest helps make the Campus restaurant a welcoming and healthy place at the heart of our community.






 Prof. Martin Vetterli, EPFL, third from left

**2024: A YEAR OF SCIENTIFIC
BREAKTHROUGHS AND TECHNOLOGICAL
INNOVATIONS UNDER THE PRESIDENCY
OF PROF. MARTIN VETTERLI, EPFL**

Research & Innovation

The year 2024 was marked by major scientific advances (resulting in 37 scientific articles) and significant technological innovations at Campus Biotech. Thanks to state-of-the-art infrastructure and interdisciplinary collaborations between neuroscientists, multidisciplinary researchers, engineers and clinicians, new horizons were explored in neurotechnology research, advanced imaging, and digital health.

Prof. Denis Jabaudon	Roger de Spoelberch & Gill Institute Award
Prof. Jordan Squair	Bayer Foundation Early Excellence in Science Award
Prof. Mackenzie et Prof. Alexander Mathis	Robert Bing Award
Prof. Mackenzie Mathis	Latsis Award
Prof. Friedhelm Hummel	Fürst Donnersmack Award
Prof. Dimitri Van de Ville	IEEE EMBS Technical Achievement Award
Prof. Nako Nakatsuka	ACS Measurement Science Rising Star Award 2024
Prof. Sophie Schwartz	Richard Benson Award
Prof. Panteleimon Giannakopoulos	SNMMI grant recipient
Prof. Grégoire Courtine	ERC grant
Prof. Fides Zenk	ERC grant
Prof. Martin Schrimpf	SNSF Spark grant



Evolving Language

The National Center of Competence in Research (NCCR) Evolving Language is a national, interdisciplinary research consortium of humanities, computer, social and natural sciences. The collaborative goal is to solve one of the greatest mysteries of human existence: what is language? How did our species develop this ability to express ourselves verbally, process language in our brains, and constantly pass on new linguistic variations to future generations? How will our language skills change in the face of new media and neuroengineering? The year 2024 saw the consolidation of this FCBG partner National Research Center through the UNIGE teams with the start of phase 2 and the integration of new academic partners into the consortium.



<https://evolvinglanguage.ch>

An AI model to better understand animal body language

Behavioral analysis can provide a wealth of information about the health or intentions of a living being. A technology developed at EPFL by Prof. Mackenzie Mathis's group enables a deep learning model to do this in a natural environment. Published in Nature Communications, this "foundational model" called SuperAnimal, that can be used to explore behavior of dozens of species, will be useful in animal protection, biomedicine, and neuroscience research.



<https://doi.org/10.1038/s41467-024-48792-2>

The origins of brain connections: when genes shape our brains

A study conducted by Prof. Jabaudon's group at UNIGE, published in Nature in October 2024, provides insights how specific genetic programs guide the formation of descending pathways in the cerebral cortex. These neural connections play a key role in the proper functioning of the brain. Understanding their development opens up new avenues for better understanding of neurological disorders related to these circuits, such as certain forms of paralysis or motor disorders. These findings represent a major advance in our understanding of the human brain.



<https://doi.org/10.1038/s41586-024-07895-y>



Stimulation of the hypothalamus enables paralyzed patients to walk again

An unexpected discovery of a brain region crucial for restoring the ability to walk in mice with spinal cord injuries has led to deep brain stimulation therapy in humans. Two patients with partial spinal cord injuries were able to regain control of their legs sufficient to walk without assistance and even climb stairs. The study published in Nature Medicine by Prof. Courtine's group (EPFL) revealed that the technique does not only produce immediate results in improving walking ability during rehabilitation, but provides also long-term improvements that persisted after stimulation was stopped.



<https://doi.org/10.1038/s41591-024-03306-x>

When the brain no longer responds to rewards: a key to untangle underlying causes of schizophrenia or pathology of schizophrenia

A recent study conducted by Prof. Kaiser's group at UNIGE, published in journal Brain, reveals a new mechanism underlying the apathy observed in patients with schizophrenia. By analyzing how their brains respond (or fail to respond) to rewards, the researchers identified specific alterations linked to this condition. These findings pave the way for new therapeutic opportunities that directly target the involved neuronal circuits, offering hope for improving patients' quality of life.



<https://doi.org/10.1093/brain/awae112>

Visit of the President of Estonia: genomics and healthcare innovation at the core

In 2024, Campus Biotech had the honor of welcoming the President of Estonia on an official visit dedicated to innovation and advances in genomics. Accompanied by a delegation of Estonian government representatives, startup and academic sector, he discovered the cutting-edge platforms in the Campus, including the Genome Center, which greatly impressed him.

The visit of the President, who himself is a neuroscientist, provided an opportunity to discuss potential synergies and institutional collaborations between Switzerland and Estonia, two nations committed to healthcare innovation. The covered topics included digital health, neuroengineering, and artificial intelligence, paving the way for potential future scientific and technological cooperation.



NEURO-Connect

LAUNCH OF NEURO-CONNECT CONFERENCE SERIES: A NEW FORUM FOR SCIENTIFIC EXCHANGE

In 2024, the FCBG launched NEURO-Connect, a new series of conferences dedicated to neuroscience and neurotechnology. This initiative aims to promote exchanges between researchers, clinicians, engineers, and entrepreneurs by inviting world-class speakers to present the latest scientific advances in these fields.

Funded entirely by the FCBG and organized in collaboration with EPFL, UNIGE, HUG, and the Wyss Center, the NEURO-Connect conferences welcome around 20 internationally renowned speakers each year. Each session includes a scientific presentation followed by an interactive roundtable, allowing for an enriching dialogue with the Campus community. A special opportunity is also provided for doctoral and postdoctoral students, who can talk directly with the guest speaker during a small lunch.

This revamped format, which replaces the former Brain & Cognition colloquiums, and continues to offer a more dynamic and inclusive program, ensuring thematic and institutional diversity. With its balanced governance and structured funding model, NEURO-Connect has established itself as a must-go event, strengthening ties between academic and industrial players on the Campus Biotech.

« By bringing together international experts and creating open spaces for discussion, NEURO-Connect conferences stimulate innovative ideas and strengthen synergies between disciplines. This is a real asset for the scientific excellence at the Campus Biotech. »

— Prof. David Sander, Director of CISA, UNIGE and member of the Academic Council

Financials

The year 2024 marks an important milestone for FCBG with the inclusion of a financial presentation in our annual report.

The FCBG economic model relies primarily on the support of our **founding partners**, who represent the main funding source for our activities. In addition, we receive contributions from partners as donations and grants, as well as service income generated by the services provided by our platforms.

Our main expenses include the costs related to the operation of the building, such as rent and energy costs, as well as the payroll and cost of service, including consumables. Finally, equipment management also represents a significant expense, requiring rigorous planning to ensure maintenance and renewal.

The FCBG benefits from a strong financial position, supported by leading institutions. With total assets of **CHF 28.2 million** and capital and reserves of **CHF 25.6 million**, the Foundation has the necessary resources to finance its current equipment (net value of CHF **21.6 million**) and ensure continuity of operations.

Foundation's financial statements have been audited by KPMG in accordance with applicable standards. The audit confirmed that the annual accounts were in compliance with Swiss law, the foundation deed and the regulations.


The presentation of financial data has been adjusted to facilitate understanding and analysis.

Summary of Income Statement


Thousands of CHF	2024
Operating income	28,668
Operating expenses	30,380
Operating income	(1,712)
Net result from financial activities	(6)
Income before changes in fund capital	(1,717)
Change in fund capital	(823)
Net income before allocations to the organization's capital	(894)
Change in restricted reserves	1,350
Change in unrestricted reserves	456

Sources of Funding for the Foundation

Product breakdown 2024
CHF 28,668 K



Distribution of charges



Internal Control and Outlook

In 2024, we initiated an in-depth review of our internal controls in order to better document our processes and rethink our risk and control matrices. This initiative aims to enhance transparency and financial security while making our practices clearer and more tailored to the Foundation's needs.

In the coming years, our ambition is to transform the Finance department into a true strategic partner for the operational departments. We want to play an active role in supporting strategic decisions and optimizing the Foundation's resources.

With this in mind, we aim to implement initiatives designed to provide clear and relevant financial analysis tailored to the specific needs of each department.

In addition, we aim to produce financial reports that not only comply with regulatory and contractual requirements, but are also designed to be genuine tools for information and decision-making.

Finally, a key focus of our transformation will be to strengthen internal control in order to pragmatically cover the key risks associated with financial processes. We are putting in place appropriate mechanisms to guarantee the reliability of financial information and secure the Foundation's essential operations.

These developments are part of a commitment to strengthen the monitoring, rigor, and quality of financial information in support of the Foundation's mission.





Vision

for the coming year: a new dynamic driven by a strategy that reinforces the translational focus of the Campus Biotech

The coming year will mark a key milestone for FCBG, with the strategic repositioning of its communications around neuroscience and neurotechnology. The aim is to promote the influence of the founding institutions and the Canton of Geneva by highlighting the innovations and scientific collaborations that make our ecosystem a unique center of excellence.

COMPLETION OF BUILDING B4: A CATALYST FOR ENTREPRENEURIAL INNOVATION

The year 2025 will also see the completion of the new B4 building, a space dedicated primarily to startups and manufacturers. This strategic project marks a major evolution in the structure of the Campus Biotech by expanding its scope beyond academic researchers and clinicians to fully integrate entrepreneurs. Led mainly by our partner FONGIT, a space managed by Superlab ("Lab as a Service") will offer young companies a dynamic environment conducive to innovation and growth. It will thus constitute an essential anchor point for the development of new solutions in life sciences.





TOWARDS A COMPREHENSIVE AND INTEGRATED ECOSYSTEM




Since its creation, the FCBG has built an environment of research excellence, bringing together world-renowned researchers around innovative projects. The year 2024 saw the integration of a new dimension with the arrival of patients at the heart of translational research. The next step, which we will begin in 2025, will be to strengthen the presence of entrepreneurs and industry or business representatives in order to create a unique continuum between fundamental research, clinical innovation, and industrial application.

This dynamics allows the Campus Biotech to consolidate its position as a strategic location for life sciences, not only for the canton of Geneva, but also for the whole of French-speaking Switzerland. This complementarity between researchers, clinicians, patients, and entrepreneurs will place our institution at the center of the major challenges facing medicine and health technologies of tomorrow.

STRONGER COMMUNICATION FOR INTERNATIONAL INFLUENCE

In light of recent developments and our growth momentum, we will launch an ambitious initiative aimed at raising the profile of Campus Biotech on the international stage. Our unique positioning as a national center for neuroscience and neurotechnology will be highlighted through events, publications, and collaborations with key players in the field.


This new phase will provide an opportunity to raise the profile of Campus Biotech far beyond Swiss borders and attract talent, investors, and industrial partners to consolidate Campus Biotech's position as a center of excellence in biomedical and life sciences.





in







Fondation Campus Biotech Geneva (FCBG)
9, Ch. des Mines
CH-1202 Geneva, Switzerland
contact@fcbg.ch | +41 58 201 02 00
fcbg.ch